ProBioGen Signs a Commercial License Agreement with AstraZeneca Providing their GlymaxX® Technology
Berlin, Germany, February 11, 2022:
ProBioGen announces a multi-product commercial license agreement with AstraZeneca to use the GlymaxX technology.
Following evaluation of the technology under a research license, AstraZeneca will now continue to use GlymaxX and will integrate the technology into their drug discovery.
GlymaxX improves target cell killing orchestrated by natural killer cells, thereby enhances antibody-dependent cell-mediated cytotoxicity (ADCC). It is a universal, simple technology that allows modifying existing cell lines or creating new ones, demonstrating its flexibility. Another unique advantage of GlymaxX is that it allows using the same modified cell line to produce antibodies of varying levels of fucosylation.
ProBioGen's Chief Business Officer, Dr. Gabriele Schneider, said: "We are delighted that AstraZeneca decided to implement our technology, which has shown great potential in making molecules more potent and efficient."
About ProBioGen
ProBioGen is a specialist in the development and manufacturing of complex therapeutic proteins.
The combination of ProBioGen’s CHO.RiGHT® expression platform and state-of-the-art process development platforms, together with intelligent and innovative product-specific technologies yield biologics with optimized properties.
Rapid and integrated cell line and process development, comprehensive analytical development and robust GMP manufacturing is performed by a highly skilled and experienced team. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).
ProBioGen has been operational for more than 25 years. At two locations in Berlin, more than 200 employees contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work.
About GlymaxX
The GlymaxX technology, developed by ProBioGen, prevents the addition of the sugar "fucose" to the N-linked antibody carbohydrate part by antibody producing cells. The absence of fucose enhances ADCC (antibody-dependent cell-mediated cytotoxicity) activity for antibodies directed against cancer and infectious diseases. The GlymaxX technology is based on the stable introduction of a gene for an enzyme which deflects the cellular pathway of fucose biosynthesis. ProBioGen offers this technology royalty-free to third parties. GlymaxX has been widely applied worldwide in the biotech and pharma industry to produce afucosylated molecules
ProBioGen Contact:
Dr. Gabriele Schneider
Chief Business Officer
cdmo@probiogen.de
+49 (0)30 3229 35 100
www.probiogen.de